315 related articles for article (PubMed ID: 9892605)
1. Interleukin 12 protects from a T helper type 1-mediated autoimmune disease, experimental autoimmune uveitis, through a mechanism involving interferon gamma, nitric oxide, and apoptosis.
Tarrant TK; Silver PB; Wahlsten JL; Rizzo LV; Chan CC; Wiggert B; Caspi RR
J Exp Med; 1999 Jan; 189(2):219-30. PubMed ID: 9892605
[TBL] [Abstract][Full Text] [Related]
2. IFN-gamma-deficient mice develop experimental autoimmune uveitis in the context of a deviant effector response.
Jones LS; Rizzo LV; Agarwal RK; Tarrant TK; Chan CC; Wiggert B; Caspi RR
J Immunol; 1997 Jun; 158(12):5997-6005. PubMed ID: 9190954
[TBL] [Abstract][Full Text] [Related]
3. Endogenous IL-12 is required for induction and expression of experimental autoimmune uveitis.
Tarrant TK; Silver PB; Chan CC; Wiggert B; Caspi RR
J Immunol; 1998 Jul; 161(1):122-7. PubMed ID: 9647215
[TBL] [Abstract][Full Text] [Related]
4. Protective effect of the type IV phosphodiesterase inhibitor rolipram in EAU: protection is independent of IL-10-inducing activity.
Xu H; Strassmann G; Chan CC; Rizzo LV; Silver PB; Wiggert B; Caspi RR
Invest Ophthalmol Vis Sci; 1999 Apr; 40(5):942-50. PubMed ID: 10102291
[TBL] [Abstract][Full Text] [Related]
5. CTLA4-Ig suppresses development of experimental autoimmune uveitis in the induction and effector phases: Comparison with blockade of interleukin-6.
Iwahashi C; Fujimoto M; Nomura S; Serada S; Nakai K; Ohguro N; Nishida K; Naka T
Exp Eye Res; 2015 Nov; 140():53-64. PubMed ID: 26297802
[TBL] [Abstract][Full Text] [Related]
6. Uveitogenicity is associated with a Th1-like lymphokine profile: cytokine-dependent modulation of early and committed effector T cells in experimental autoimmune uveitis.
Xu H; Rizzo LV; Silver PB; Caspi RR
Cell Immunol; 1997 May; 178(1):69-78. PubMed ID: 9184700
[TBL] [Abstract][Full Text] [Related]
7. Autoimmunity to a pathogenic retinal antigen begins as a balanced cytokine response that polarizes towards type 1 in a disease-susceptible and towards type 2 in a disease-resistant genotype.
Sun B; Sun SH; Chan CC; Wiggert B; Caspi RR
Int Immunol; 1999 Aug; 11(8):1307-12. PubMed ID: 10421788
[TBL] [Abstract][Full Text] [Related]
8. SLAT/Def6 plays a critical role in the pathogenic process of experimental autoimmune uveitis (EAU).
Vistica BP; Shi G; Nugent L; Tan C; Altman A; Gery I
Mol Vis; 2012; 18():1858-64. PubMed ID: 22815639
[TBL] [Abstract][Full Text] [Related]
9. Differentiation of Th1 and Th2 cells in lymph nodes and spleens of mice during experimental autoimmune uveoretinitis.
Takeuchi M; Yokoi H; Tsukahara R; Sakai J; Usui M
Jpn J Ophthalmol; 2001; 45(5):463-9. PubMed ID: 11583666
[TBL] [Abstract][Full Text] [Related]
10. Exogenous nitric oxide inhibits experimental autoimmune uveoretinitis development in Lewis rats by modulation of the Th1-dependent immune response.
Kwak HJ; Yang YS; Pae HO; Kim YM; Chung HT
Mol Cells; 2001 Oct; 12(2):178-84. PubMed ID: 11710518
[TBL] [Abstract][Full Text] [Related]
11. Delayed onset and decreased severity of experimental autoimmune uveoretinitis in mice lacking nitric oxide synthase type 2.
Thillaye-Goldenberg B; Goureau O; Naud MC; de Kozak Y
J Neuroimmunol; 2000 Oct; 110(1-2):31-44. PubMed ID: 11024532
[TBL] [Abstract][Full Text] [Related]
12. Mice deficient in inducible nitric oxide synthase are susceptible to experimental autoimmune uveoretinitis.
Silver PB; Tarrant TK; Chan CC; Wiggert B; Caspi RR
Invest Ophthalmol Vis Sci; 1999 May; 40(6):1280-4. PubMed ID: 10235566
[TBL] [Abstract][Full Text] [Related]
13. Characterization of IL-17+ interphotoreceptor retinoid-binding protein-specific T cells in experimental autoimmune uveitis.
Peng Y; Han G; Shao H; Wang Y; Kaplan HJ; Sun D
Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4153-61. PubMed ID: 17724201
[TBL] [Abstract][Full Text] [Related]
14. Activation of invariant NKT cells ameliorates experimental ocular autoimmunity by a mechanism involving innate IFN-gamma production and dampening of the adaptive Th1 and Th17 responses.
Grajewski RS; Hansen AM; Agarwal RK; Kronenberg M; Sidobre S; Su SB; Silver PB; Tsuji M; Franck RW; Lawton AP; Chan CC; Caspi RR
J Immunol; 2008 Oct; 181(7):4791-7. PubMed ID: 18802082
[TBL] [Abstract][Full Text] [Related]
15. Blockade of interleukin-6 signaling suppresses not only th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis.
Haruta H; Ohguro N; Fujimoto M; Hohki S; Terabe F; Serada S; Nomura S; Nishida K; Kishimoto T; Naka T
Invest Ophthalmol Vis Sci; 2011 May; 52(6):3264-71. PubMed ID: 21330657
[TBL] [Abstract][Full Text] [Related]
16. Endogenous systemic IFN-gamma has a protective role against ocular autoimmunity in mice.
Caspi RR; Chan CC; Grubbs BG; Silver PB; Wiggert B; Parsa CF; Bahmanyar S; Billiau A; Heremans H
J Immunol; 1994 Jan; 152(2):890-9. PubMed ID: 8283058
[TBL] [Abstract][Full Text] [Related]
17. Abrogation of anti-retinal autoimmunity in IL-10 transgenic mice due to reduced T cell priming and inhibition of disease effector mechanisms.
Agarwal RK; Horai R; Viley AM; Silver PB; Grajewski RS; Su SB; Yazdani AT; Zhu W; Kronenberg M; Murray PJ; Rutschman RL; Chan CC; Caspi RR
J Immunol; 2008 Apr; 180(8):5423-9. PubMed ID: 18390724
[TBL] [Abstract][Full Text] [Related]
18. S-nitrosoglutathione prevents interphotoreceptor retinoid-binding protein (IRBP(161-180))-induced experimental autoimmune uveitis.
Haq E; Rohrer B; Nath N; Crosson CE; Singh I
J Ocul Pharmacol Ther; 2007 Jun; 23(3):221-31. PubMed ID: 17593005
[TBL] [Abstract][Full Text] [Related]
19. Residues 1-20 of IRBP and whole IRBP elicit different uveitogenic and immunological responses in interferon gamma deficient mice.
Avichezer D; Chan CC; Silver PB; Wiggert B; Caspi RR
Exp Eye Res; 2000 Aug; 71(2):111-8. PubMed ID: 10930316
[TBL] [Abstract][Full Text] [Related]
20. CCR5-deficient mice develop experimental autoimmune uveoretinitis in the context of a deviant effector response.
Takeuchi A; Usui Y; Takeuchi M; Hattori T; Kezuka T; Suzuki J; Okunuki Y; Iwasaki T; Haino M; Matsushima K; Usui M
Invest Ophthalmol Vis Sci; 2005 Oct; 46(10):3753-60. PubMed ID: 16186359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
